- Theralase (TLT) has expanded its intellectual property portfolio regarding photo dynamic compounds
- The patent advances its anti-cancer technology, including its lead TLD-1433 compound, which is currently in phase II trials for bladder cancer in Canada and the U.S.
- The company’s photo dynamic compounds are designed to produce free radicals to destroy cancer cells from within
- Theralase Technologies is a clinical-stage pharmaceutical company focused on light-activated photo dynamic compounds
- Theralase (TLT) is down by 7.25 per cent trading at $0.32 per share
Theralase (TLT) has expanded its intellectual property portfolio regarding photo dynamic compounds.
The company’s photo dynamic compounds are designed to produce free radicals to destroy cancer cells from within with minimal impact on healthy cells.
The patent – “Metal-Based Thiopene Photodynamic Compounds and their Use” – advances the company’s anti-cancer technology, including its lead TLD-1433 compound approved by Health Canada for a phase II non-muscle invasive bladder cancer (NMIBC) clinical study.
The company has launched the phase II study in 12 sites across Canada and the U.S. with 41 patients treated.
It remains focused on providing personalized treatment for cancer patients to “hunt and destroy” their cancer and prevent its recurrence and progression.
“This patent is strategic to opening up new international opportunities for Theralase by expanding its IP portfolio of medical laser and oncology focused technologies internationally,” stated Arkady Mandel, Theralase’s CSO and Interim CEO. “Theralase’s long-term strategy is to commercialize the anti-cancer therapy technology commencing with NMIBC and expanding into non-small cell lung cancer, glioblastoma multiforme and other various cancer indications.”
Theralase Technologies is a clinical-stage pharmaceutical company dedicated to the research and development of light-activated photo dynamic compounds.
Theralase (TLT) is down by 7.25 per cent trading at $0.32 per share as of 10:00 am EST.
